XSpray Pharma Price To Book vs. Net Income

XSPRAY Stock  SEK 45.65  0.25  0.55%   
Based on the key profitability measurements obtained from XSpray Pharma's financial statements, XSpray Pharma AB may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in January. Profitability indicators assess XSpray Pharma's ability to earn profits and add value for shareholders.
For XSpray Pharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of XSpray Pharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well XSpray Pharma AB utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between XSpray Pharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of XSpray Pharma AB over time as well as its relative position and ranking within its peers.
  
Check out Your Current Watchlist.
Please note, there is a significant difference between XSpray Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if XSpray Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, XSpray Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

XSpray Pharma AB Net Income vs. Price To Book Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining XSpray Pharma's current stock value. Our valuation model uses many indicators to compare XSpray Pharma value to that of its competitors to determine the firm's financial worth.
XSpray Pharma AB is rated fourth in price to book category among its peers. It is rated first in net income category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value XSpray Pharma by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for XSpray Pharma's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

XSpray Net Income vs. Price To Book

Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.

XSpray Pharma

P/B

 = 

MV Per Share

BV Per Share

 = 
2.35 X
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.

XSpray Pharma

Net Income

 = 

(Rev + Gain)

-

(Exp + Loss)

 = 
(96.7 M)
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.

XSpray Net Income Comparison

XSpray Pharma is currently under evaluation in net income category among its peers.

XSpray Pharma Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in XSpray Pharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, XSpray Pharma will eventually generate negative long term returns. The profitability progress is the general direction of XSpray Pharma's change in net profit over the period of time. It can combine multiple indicators of XSpray Pharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Xspray Pharma AB engages in developing protein kinase inhibitors for targeted cancer treatments in Sweden. Xspray Pharma AB was founded in 2003 and is based in Solna, Sweden. Xspray Pharma is traded on Stockholm Stock Exchange in Sweden.

XSpray Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on XSpray Pharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of XSpray Pharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the XSpray Pharma's important profitability drivers and their relationship over time.

Use XSpray Pharma in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if XSpray Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in XSpray Pharma will appreciate offsetting losses from the drop in the long position's value.

XSpray Pharma Pair Trading

XSpray Pharma AB Pair Trading Analysis

The ability to find closely correlated positions to XSpray Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace XSpray Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back XSpray Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling XSpray Pharma AB to buy it.
The correlation of XSpray Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as XSpray Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if XSpray Pharma AB moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for XSpray Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your XSpray Pharma position

In addition to having XSpray Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Railroads Thematic Idea Now

Railroads
Railroads Theme
Companies involved in manufacturing and maintenance of freight railroads and passenger trains as well as providing railroad services to public. The Railroads theme has 38 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Railroads Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in XSpray Stock

To fully project XSpray Pharma's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of XSpray Pharma AB at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include XSpray Pharma's income statement, its balance sheet, and the statement of cash flows.
Potential XSpray Pharma investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although XSpray Pharma investors may work on each financial statement separately, they are all related. The changes in XSpray Pharma's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on XSpray Pharma's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.